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Abstract
We review the growing number of economic evaluations of individual point-of-care (POC) tests for diagnosis of infectious diseases in
resource-limited settings that use either cohort studies or mathematical models. We focus on studies that evaluate POC diagnostic tests
for the control of human immunodeﬁciency virus (HIV) and malaria, tools that are central to the WHO prevention guidelines for infec-
tious diseases in developing countries. Although rapid diagnostic tests for HIV and malaria seem to be cost-effective in these standard
analyses, these do not take into account the reduction in patients’ waiting time and the number of clinic visits required to receive results,
or future beneﬁts from the reduction in antimalarial drug pressure. Those additional cost reductions would be considerably greater with
POC rapid tests, and the cost-effectiveness of POC tests would therefore be improved. Findings from cost-effectiveness analyses suggest
that, despite the relatively small additional cost incurred, decision-makers should strongly consider using POC tests throughout or during
parts of HIV and malaria epidemics, where this is feasible in terms of local human resources and logistical conditions.
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Introduction
Recent ﬁgures from the WHO [1] suggest that 33 million
individuals are living with HIV infection worldwide, more
than two-thirds in developing countries with limited
resources. The scale-up of antiretroviral therapy (ART) in
low-income and middle-income countries has been unprece-
dented, with more than 4 million people estimated to have
had access to ART at the end of 2008 [1]. Despite the global
effort to control the AIDS pandemic, human immunodeﬁ-
ciency virus (HIV) infection continues to spread relatively
unabated in many parts of the world. The transmission rate
for HIV-infected individuals unaware of their infection is up
to 3.5-fold higher than that for those who are aware [2].
Identifying those who are acutely HIV-infected is a ﬁrst pri-
ority in order to reduce transmission rates through the use
of both behavioural interventions and effective treatment
programmes. Expansion of HIV testing is therefore urgently
required, and mechanisms must be developed to ensure that
HIV diagnosis occurs early on in the course of disease, at
affordable costs, especially for people living in resource-lim-
ited countries.
The same holds true for malaria. Its diagnosis has tradi-
tionally relied on the clinical presentation of disease symp-
toms and microscopic examination of Giemsa-stained blood
ﬁlms [3]. Diagnosis based on symptoms alone is unreliable,
because the symptoms of malaria are non-speciﬁc, overlap-
ping with those of other febrile diseases [4]. Studies in Africa
have shown that between 50% and 99% of those clinically
diagnosed with malaria and then prescribed antimalarial drugs
have illnesses attributable to some other cause, depending
on endemicity in the clinical setting [5,6]. This results in
overdiagnosis of malaria and overprescription of antimalarial
drugs, as well as underdiagnosis and inappropriate treatment
of non-malarial febrile illnesses [7,8]. In addition, antimalarial
drug pressure ultimately contributes to the development
and spread of drug resistance [9]. Most victims of malaria
still die because the disease is not diagnosed in time by
health workers [10].
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It appears that existing diagnosis technologies are poorly
adapted for use in resource-limited settings. ‘‘Current tech-
nologies are very expensive and require delicate instruments,
cold chain, and stable electricity, which are not available in
areas where the majority of the patients reside’’ [11]. In
addition, when testing is carried out in centralized laborato-
ries, turn-around times are of the order of several months
for specimens sent from rural areas in developing countries
[12,13].
How can high-quality test results be provided in the most
cost-effective way? One solution is the use of point-of-care
(POC) tests. These are diagnostic tests performed close to
the patient. They require less laboratory infrastructure, are
potentially cheaper, and can be designed to be easy to use
and interpret [14–16]. These advantages can help reduce the
workload for laboratories and streamline care in settings
where large numbers of patients are treated daily. In addition
to improving the standard of care, a test that can be per-
formed while the patient is at the clinic means that fewer
patients are lost to follow-up and the burden on patients is
reduced [11]. Because the procedures are very simple (the
need for equipment such as centrifuges and electricity being
eliminated), involve a limited number of steps, and do not
require high precision, they can be used outside tradi-
tional laboratory settings by staff with no formal laboratory
training.
In the face of economic constraints, it is critically impor-
tant to evaluate how best to utilize available resources
[17,18]. Cost-effectiveness analysis is a well-established meth-
odology for understanding, prioritizing and optimizing health-
care services. By comparing testing alternatives in terms of
their relative advantages and costs, cost-effectiveness analysis
can serve as one key element to inform decision-makers, in
order to deﬁne public health policy [19].
In this article, we review the growing number of economic
evaluations of individual POC tests for diagnosis of infectious
diseases in resource-limited settings that use either cohort
studies or mathematical models. We focus on studies that
evaluate POC diagnostic tests for the control of HIV and
malaria, tools that are central to the WHO prevention
guidelines for infectious diseases in developing countries.
Review of Recent Studies on the Cost-
effectiveness of ART
We used the Medline database to conduct a literature search
of articles published between 2006 and 2010. We then
reviewed citation and reference lists to identify additional
studies. Table 1 provides a summary of the results and
describes the methodological features of each analysis that
evaluates the cost-effectiveness of POC diagnostic tests for
HIV disease and malaria.
Cost-effectiveness of Rapid POC Diagnostic
Tests for the Control of HIV
In 1992, the Global Programme on AIDS and the WHO ﬁrst
recommended the use of testing strategies based on combi-
nations of screening tests (including simple, rapid tests) for
blood screening, surveillance, and diagnosis, instead of the
enzyme immunoassay and western blot techniques previously
used [20]. Although these recommendations were revised as
the range of antibody tests expanded, they were still
intended for serum or plasma testing. Instead, recently devel-
oped rapid tests detect HIV antibodies in whole blood speci-
mens, making it possible to evaluate the performance and
the cost-effectiveness of POC HIV testing in settings with
limited laboratory facilities and where the demand for volun-
tary counselling testing is likely to increase.
For several reasons, the expanded use of POC rapid HIV
testing promises to play an important role in HIV prevention,
both in developed and in developing countries. First, access
to immediate HIV test results could improve the application
of prophylactic regimens to reduce vertical transmission
when used intrapartum or postpartum [21–23]. In line with
this objective, Menzies et al. [24] studied the cost-effective-
ness of initiating diagnosis with a rapid HIV test to screen
out HIV-uninfected infants. The comparator that they used
was the current diagnosis-testing algorithm DNA-PCR. The
study population comprised HIV-exposed children
<18 months of age attending two postnatal screening pro-
grammes in Uganda between 2005 and 2006. The authors
used a decision-analytical model to compare the DNA-PCR
and rapid HIV test approaches, and found that the former
identiﬁed 94.3% (91.8–94.7%) of HIV-infected infants, as
compared with 87.8% (79.4–90.5%) for the latter. Moreover,
the total cost of the POC testing programme was about 40%
less than that of DNA-PCR ($59 vs. $38 per infant aged
6–9 months). The rapid POC test is therefore more cost-
effective than the comparator, as the incremental cost per
HIV-infected infant correctly diagnosed using the latter ranges
from $559 (95% CI $261–$2702) with low compliance to
$7165 (95% CI: $3322–20 127) with perfect compliance.
Second, as several studies indicate that persons who are
aware of their HIV infection more frequently adopt behav-
iours to reduce the likelihood of transmission [25–27], the
use of rapid tests as a tool for prevention strategies promot-
ing the need for awareness of one’s own and one’s partner’s
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infection status could considerably reduce HIV sexual trans-
mission. Vickerman et al. [28] studied the impact of com-
bined Neisseria gonorrhoeae/Chlamydia trachomatis rapid POC
tests on the transmission of HIV or sexually transmitted
infections among female sex workers, their clients and the
general population in Cotonou, Benin. Using a deterministic
model and data from the SIDA2 trial [29], the authors
showed that rapid POC tests constitute a cost-effective use
of resources for increasing the impact of treatment inter-
ventions for sexually transmitted infections in resource-poor
settings, even though they cost up to $4 per test. The rapid
POC tests resulted in 10% of N. gonorrhoeae/C. trachomatis
cases being averted and 6% of HIV cases being averted, the
incremental cost per HIV infection averted being $292.2
(95% CI 224.7–472.6), and the initial test costing $4. How-
ever, the authors argued that they used the lower cost
range for the combined N. gonorrhoeae/C. trachomatis test on
the grounds that more expensive tests would no longer be
cost-effective. Failing to explore the potential impact of the
higher costs possibly biased their results in favour of POC
testing, making it appear more cost-effective than it may
actually be in practice.
Third, POC tests considerably reduce patient anxiety, the
adverse effects of waiting for one’s test results, and also the
risk of loss to follow-up [30,31]. In a recent study con-
ducted in the USA, Sanders et al. [32] examined the costs
and beneﬁts of three strategies to improve HIV testing and
receipt of results among primary-care patients with
unknown HIV status: (i) traditional HIV counselling and test-
ing; (ii) nurse-initiated routine screening with traditional
counselling and testing; and (iii) nurse-initiated routine
screening with streamlined counselling and rapid HIV testing.
On the basis of a Markov model, data from randomized
controlled trials, and assumptions when necessary, the
authors showed that nurse-initiated routine screening with
traditional counselling and testing increased rates of testing
and improved receipt of test results, and was also cost-
effective as compared with traditional HIV-testing strategies.
With rapid testing by nurses, life-expectancy was increased
by 0.87 years or 0.63 quality-adjusted life-years as compared
with traditional counselling and testing. Including the bene-
ﬁts from reduced transmission, the additional gains in health
beneﬁt with rapid testing cost $10 660/QALY.
Although rapid diagnostic tests for HIV seem to be cost-
effective in these standard analyses, these do not take into
account the reduction in patient waiting time and the num-
ber of clinic visits required to receive results. Those addi-
tional costs would be considerably reduced with POC rapid
tests, and the cost-effectiveness of POC tests for HIV would
therefore be improved.T
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Cost-effectiveness of Rapid POC Diagnostic
Tests in the Diagnosis of Malaria
As antimalarial drug costs increase, diagnostic methods are
becoming a crucial component of malaria control and pre-
vention, and there is an increased need to ensure that
malaria is correctly diagnosed prior to treatment. For exam-
ple, in 39 African countries, as a result of extensive resis-
tance to chloroquine and sulphadoxine–pyrimethamine [33],
artemisinin-based combination therapy (ACT) has been the
ﬁrst-line antimalarial treatment since 2007. Although prices
have been reduced recently, ACT still costs up to ten times
more than chloroquine [34,35].
As regards diagnosis of the disease, the WHO [10] guide-
lines recommend that parasite-based diagnosis should be
used in all cases of suspected malaria, with the possible
exception of children in high-prevalence areas and in certain
other situations. With a presumptive antimalarial treatment
strategy, diagnostic sensitivity is maximized, and the case
management algorithm is greatly simpliﬁed. However, pre-
sumptive treatment has serious disadvantages, because of its
very poor speciﬁcity (that is, many febrile cases are diag-
nosed as malaria even though they have a different pathol-
ogy) [36,37]. In contrast, rapid diagnostic POC tests can be
performed in settings with no sophisticated infrastructure, as
they require only a minimum level of training for community
health workers in charge of diagnosis and prescription.
Despite these advances, there is a scarcity of cost-effec-
tiveness data on rapid POC tests in countries with high
malaria endemicity [38]. This review reports results from
economic evaluations carried out in developing countries to
determine whether the use of rapid POC tests for diagnosis
of malaria is cost-effective when compared with clinical and
microscopy-based diagnosis.
Using a decision tree model, Shillcutt et al. [39] conducted
a cost-effectiveness analysis in different sub-Saharan settings
to compare presumptive, ﬁeld standard microscopy and
rapid POC tests in the diagnosis of malaria. They showed
that these latter have the potential to be cost-effective in
most parts of sub-Saharan Africa, and that appropriate man-
agement of malaria and non-malarial febrile illnesses is
required to reap the full beneﬁts of this type of testing.
However, the authors acknowledged that little is known
about the impact of introducing new diagnostics on patients’
behaviour, especially in terms of facility use and adherence
to therapy. One limit of this model, as reported by the
authors, is that it considers formal outpatient facilities only,
whereas in many settings a high proportion of care-seekers
obtain drugs from private, informal ‘pharmacies’. Further
analysis of the cost-effectiveness of rapid POC tests at these
informal providers is warranted.
In the same way, Uzochukwu et al. [40] compared the
cost-effectiveness of rapid POC testing with syndromic diag-
nosis and microscopy in a hypothetical population of
100 000 patients with a history of fever or of non-speciﬁc
symptoms or signs suggestive of malaria and clinically diag-
nosed as having malaria by health workers in urban and rural
districts of Nigeria. The same decision tree used by Shillcutt
et al. was employed, and the analysis was further stratiﬁed by
age group. The incremental cost-effectiveness ratio of rapid
POC tests vs. presumptive treatment was $221 per death
averted, and microscopy was a dominated strategy (i.e. less
effective and more costly). With a malaria prevalence in the
hypothetical population of 43.1% or less, the rapid POC test
is cost-effective when compared with other diagnostic strate-
gies for malaria treatment. The authors concluded that pol-
icy-makers and healthcare providers should be aware of the
upper limit of malaria prevalence for which the use of rapid
POC tests brings about cost savings. Similarly, Zurovac et al.
[41] questioned the impact of malaria prevalence on the
cost-effectiveness of diagnostic strategies. They found that in
an area of Kenya with a high rate of malaria transmission
(between 30% and 50%), rapid POC tests would improve
malaria treatment by reducing the percentage of overtreat-
ment errors, with lower costs. In an area with a low preva-
lence of malaria (about 1.5% of all patients above 5 years of
age), rapid POC tests would yield minor reductions in over-
treatment errors, but with higher costs. According to the
authors, the limited beneﬁts obtained in low-prevalence
areas result from the underuse of ACT following the recent
introduction of a new treatment policy [42]. A follow-up
evaluation in Zambia showed that the frequency of ACT pre-
scriptions increased over 2 years, and that this increase coin-
cided with the expansion of rapid POC test capacity [43].
Similar changes in Kenya in the future would inevitably
change the current overtreatment and costs.
Msellem et al. [44] studied the inﬂuence of rapid POC tests
for malaria diagnosis on drug prescriptions, health outcomes
and costs in primary healthcare settings in Zanzibar, and com-
pared this intervention with symptom-based clinical diagnosis
alone. The authors wanted to test the hypothesis that prompt
testing of febrile patients would lead to better patient health-
care through both improved use of ACT and prescription of
more appropriate treatments, including antibiotics, to non-
malaria patients. A total of 1887 patients of all ages with
reported fever were enrolled in a non-randomized, four-cen-
tre clinical trial, and followed up for 14 days. Outcomes were
analysed with a multilevel modelling approach, although pri-
mary outcome and costs were not combined in the form of a
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cost-effectiveness ratio. The results showed an overall two-
fold reduction in the prescription of antimalarial drugs and re-
attendance of patients because of illness during the 2-week fol-
low-up period in patients within the POC group. Overall costs
were, however, similar in the POC and clinical diagnosis
groups, despite a signiﬁcant reduction of costs among the adult
patients after rapid POC testing. In addition, the introduction
of rapid POC testing resulted in cost savings in patients aged
over 15 years (malaria treatment being reduced to less than
20% of febrile patients in this population). An important piece
of information added by this study is that the false-negative
results with POC testing (i.e. patients detected by microscopy
but not detectable by POC testing) did not develop any severe
manifestations during the 2 weeks of follow-up. This supports
the general recommendation for consistency in not treating
rapid POC test-negative patients. Obviously, retesting is
required if the illness remains and becomes aggravated. In this
study, nurses and patients showed great conﬁdence in the
POC test results as a guide to the choice of treatment to be
prescribed. Strong compliance by prescribers with practice
guidelines, when rapid diagnostic test results prove to be nega-
tive, was also reported in a recent study conducted in main-
land Tanzania [45]. These ﬁndings are in contrast, however, to
those from other studies showing that care providers,
although willing to perform diagnostic tests, do not always
comply with recommended practices [6,9,46]. As demon-
strated by Lubell et al. [47], using an economic evaluation and
taking into account clinicians’ responses to test results, this
would affect the cost-effectiveness of rapid diagnostic tests.
Therefore, it is important that policy-makers make efforts to
encourage health workers to use the test results as a guide for
treatment decisions.
Although these models do not address what potential inter-
ventions would be needed to improve healthcare providers’
behaviours (e.g. training, supervision, strengthening of drug
and rapid diagnostic test supplies, and additional personnel)
and the costs of such interventions, these analyses nonetheless
provide better information about their potential impacts.
Further work is needed to determine what future beneﬁts can
be obtained from the reduction in antimalarial drug pressure.
Such beneﬁts include a deceleration in the development of
antimalarial resistance and improved antibiotic drug prescrip-
tion thanks to enhanced speciﬁcity of malaria diagnosis.
Conclusions
Over the past decade, POC testing has become increasingly
accessible in areas with limited laboratory facilities, resulting
in a great reduction in the number of persons who do not
receive their test results. It can also immediately provide the
test results needed to make decisions about treatment.
Highly sensitive and speciﬁc POC diagnostic tests, given their
ease of use and interpretation, could potentially be deployed
at a peripheral level in epidemics, if a minimal degree of per-
sonnel training, logistics and quality assurance is guaranteed
[48]. From the ﬁnancial standpoint, the public health
improvement inherent in the deployment of POC diagnostic
tests might result in either additional immediate expenditures
(because of the cost of testing) or signiﬁcant long-term sav-
ings (because of effective control of HIV and malaria). Fur-
ther data are required to more accurately deﬁne cost-
efﬁcacy-type models, especially when evaluating the clinical
and economic consequences of misdiagnosis. Findings from
cost-effectiveness analyses suggest that, despite the relatively
small additional cost incurred, decision-makers should
strongly consider using POC tests throughout or during
parts of HIV and malaria epidemics, where this is feasible in
terms of local human resources and logistical conditions.
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